Titan Medical Inc. (TMD.TO)
| Previous close | 0.0600 |
| Open | 0.0550 |
| Bid | 0.0550 x 0 |
| Ask | 0.0650 x 0 |
| Day's range | 0.0550 - 0.0600 |
| 52-week range | 0.0550 - 0.2600 |
| Volume | |
| Avg. volume | 68,724 |
| Market cap | 6.272M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | 0.69 |
| EPS (TTM) | 0.0800 |
| Earnings date | 07 Jun 2024 - 11 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTitan Provides Update on Planned Merger with Conavi
TORONTO, Ontario, April 22, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”). As previously announced, Titan has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock trans
- GlobeNewswire
Titan Settles Contractual Dispute with Contract Manufacturer
TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”). Titan has reached a settlement agreement in connection with a dispute with the Contractor. Under the terms of the settlement, Titan has agreed to pay the Contractor an aggregate of US$2 million, with the final payment installment to be made on or before June 24, 2024. Upon receipt of the ful
- GlobeNewswire
Titan Medical Reports Fiscal Year 2023 Results
TORONTO, Ontario, March 29, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel O’Brien, MD, MBA, Ph.D to its Board of Directors.On August 21, 2023, the Company announced a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech Company.On October 18, 2023, the Company a
